Cargando…

Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors

Detalles Bibliográficos
Autores principales:	Knight, Emily A., Osunsuyi-Fagbemi, Sylvia, Neely, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017545/ https://www.ncbi.nlm.nih.gov/pubmed/27648344

Ejemplares similares

Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications
por: Gerds, Aaron T., et al.
Publicado: (2022)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
por: Randhawa, Jasleen, et al.
Publicado: (2012)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Primary Myelofibrosis-Related Renal Disorders Treated with a Janus Kinase Inhibitor
por: Asou, Mea, et al.
Publicado: (2021)

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

Janus Kinase V617F Mutation Detection in Patients with Myelofibrosis
por: Nikolova, D, et al.
Publicado: (2019)

The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
por: Kim, Jin-Woo, et al.
Publicado: (2021)

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis
por: Sureau, Léa, et al.
Publicado: (2021)

Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trial
por: Zhang, Yi, et al.
Publicado: (2022)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Publicado: (2013)

Synchrotron Fourier Transform Infrared Microscopy Spectra in Cellular Effects of Janus Kinase Inhibitors on Myelofibrosis Cancer Cells
por: Siriwaseree, Jeeraprapa, et al.
Publicado: (2022)

Janus kinase inhibitors: jackpot or potluck?
por: Pavithran, Keechilat, et al.
Publicado: (2012)

Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis
por: Miyawaki, Hiroshi, et al.
Publicado: (2019)

Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease
por: Huo, Rongxiu, et al.
Publicado: (2022)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
por: BALLANGER, Fabienne, et al.
Publicado: (2023)

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
por: Veale, Douglas J, et al.
Publicado: (2019)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Role of Janus Kinase Inhibitors in Therapy of Psoriasis
por: Słuczanowska-Głąbowska, Sylwia, et al.
Publicado: (2021)

Itch and Janus Kinase Inhibitors
por: HAN, Yujin, et al.
Publicado: (2023)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
por: Ayala, Rosa, et al.
Publicado: (2023)

Role of janus kinase inhibitors in the treatment of alopecia areata
por: Triyangkulsri, Korn, et al.
Publicado: (2018)

The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
por: De Vries, L.C.S., et al.
Publicado: (2017)

Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
por: Núñez, Paulina, et al.
Publicado: (2023)

Janus Kinases in Leukemia
por: Raivola, Juuli, et al.
Publicado: (2021)

Janus Kinase Inhibitors and Cell Therapy
por: Assal, Amer, et al.
Publicado: (2021)

Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
por: Singh, Rhea, et al.
Publicado: (2020)

The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights
por: Toussirot, Eric
Publicado: (2022)

Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
por: Richardson, Peter J., et al.
Publicado: (2023)

Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
por: Praveen, D., et al.
Publicado: (2020)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
por: Chen, Miao, et al.
Publicado: (2020)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
por: Kotyla, Przemyslaw J.
Publicado: (2018)

Clinical significance of Janus Kinase inhibitor selectivity
por: Choy, Ernest H
Publicado: (2019)

Janus kinase inhibitors in autoimmune bullous diseases
por: Huang, Dawei, et al.
Publicado: (2023)

A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
por: Tanaka, Yoshiya
Publicado: (2023)

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
por: Huo, Rongxiu, et al.
Publicado: (2023)

Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis
por: Paroli, Marino, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_biqvr2pfut7c0kc7gudrn0fjul